SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Equillium, Inc.
Date: Sept. 11, 2025 · CIK: 0001746466 · Accession: 0000000000-25-009869

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-290138

Date
September 11, 2025
Author
Division of
Form
UPLOAD
Company
Equillium, Inc.

Letter

Re: Equillium, Inc. Registration Statement on Form S-3 Filed September 9, 2025 File No. 333-290138 Dear Bruce Steel:

September 11, 2025

Bruce Steel President and Chief Executive Officer Equillium, Inc. 2223 Avenida de la Playa, Suite 105 La Jolla, CA 92037

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Dylan Kornbluth

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 September 11, 2025

Bruce Steel
President and Chief Executive Officer
Equillium, Inc.
2223 Avenida de la Playa, Suite 105
La Jolla, CA 92037

 Re: Equillium, Inc.
 Registration Statement on Form S-3
 Filed September 9, 2025
 File No. 333-290138
Dear Bruce Steel:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jason Drory at 202-551-8342 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Dylan Kornbluth
</TEXT>
</DOCUMENT>